BIO
Simona Stankeviciute, M.D., M.Sc.
Vice President, Technical, Regulatory Consulting
Prior to joining Parexel, Simona served as a clinical and clinical pharmacology assessor for centralized procedures at the Lithuanian State Medicines Control Agency, and she served as an alternate member of EMA’s Committee for Medicinal Products for Human Use. She was also trained in health-technology assessment for medicines and has served as a head of HTA unit. She has regulatory and clinical expertise in multiple therapeutic areas—including dermatology, neurology, and infectious disease—and modalities, including advanced therapy medicinal products, biologics, and small molecules. She helps Parexel clients prepare for scientific advice meetings with the EMA; submit marketing-authorization applications, line extensions, and Type II variations; and perform advanced pharmacokinetics, pharmacodynamics, and basic modeling and simulations. In addition to experience with the EU regulators, Simona has had supported many sponsors with their clinical programs in the US, including interactions with US FDA.
More By This Expert
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Playbook
Anticipate regulatory expectations: Fill evidence gaps and mitigate risks
Playbook
Design for efficiency: Employ trial strategies to meet stakeholder needs
Blog
Three strategies to accelerate MASH trials in a competitive, rapidly shifting market
Blog
EMA’s evolving stance on external controls: Key takeaways and preparation strategies for sponsors
EXCLUSIVE
Blog
Wet AMD gene therapy: Success depends on a comprehensive development strategy
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Blog
Updated European Society of Cardiology guidelines: opportunities and risks for clinical trials
Blog
FDA’s final guidance on renal impairment: Assessment of the regulatory approach to inform clinical development planning
Blog
Regulatory considerations in designing clinical trials for Alzheimer’s disease
Blog
New guideline for the management of Systemic Lupus Erythematosus (SLE): Considerations for clinical development
Op-Ed
Can innovative trial designs work in neuroscience?
Podcast
Is There Room for New COAs in Neuroscience?
Video
Regulatory strategies for EU orphan drug development: Roundtable
Article
Five strategies for navigating the regulatory terrain of psychedelics
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Playbook
Anticipate regulatory expectations: Fill evidence gaps and mitigate risks
Playbook
Design for efficiency: Employ trial strategies to meet stakeholder needs
Blog
Three strategies to accelerate MASH trials in a competitive, rapidly shifting market
Blog
EMA’s evolving stance on external controls: Key takeaways and preparation strategies for sponsors
EXCLUSIVE
Blog
Wet AMD gene therapy: Success depends on a comprehensive development strategy
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Blog
Updated European Society of Cardiology guidelines: opportunities and risks for clinical trials
Blog
FDA’s final guidance on renal impairment: Assessment of the regulatory approach to inform clinical development planning
Blog
Regulatory considerations in designing clinical trials for Alzheimer’s disease
Blog
New guideline for the management of Systemic Lupus Erythematosus (SLE): Considerations for clinical development
Op-Ed
Can innovative trial designs work in neuroscience?
Podcast
Is There Room for New COAs in Neuroscience?
Video
Regulatory strategies for EU orphan drug development: Roundtable
Article
Five strategies for navigating the regulatory terrain of psychedelics
Discover the
heart of Parexel:
our people
heart of Parexel:
our people
Learn More